FRM
KZR

Fox Run Management’s Kezar Life Sciences KZR Stock Holding History

Fox Run Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,035
Closed -$63.7K – 833
2023
Q1 		$63.7K Buy
+2,035
New +$118K 0.02% 614
2022
Q2 		– Sell
-1,083
Closed -$180K – 648
2022
Q1 		$180K Buy
+1,083
New +$155K 0.1% 423

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fox Run Management's KZR Position: Q2 2023 in Review

Fox Run Management sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 2,035 shares — an estimated $63.7K sold.

Fox Run Management first reported a position in KZR in Q1 2022 and held it in 2 quarters. The position peaked at $180K in Q1 2022. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • Fox Run Management reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Fox Run Management sold 2,035 Kezar Life Sciences shares in Q2 2023, an estimated $63.7K.
  • Fox Run Management first reported a position in Kezar Life Sciences in Q1 2022 and held it in 2 quarters.
  • Fox Run Management's Kezar Life Sciences position peaked at $180K in Q1 2022.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on Fox Run Management's 13F filing for Q2 2023, filed 11 Aug 2023.